Condition (MeSH)
Myxoma
ClinicalTrials.gov lists 8 trials for Myxoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Myxoma trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 2 |
| 2020 | 1 |
| 2017 | 1 |
| 2012 | 1 |
| 2008 | 1 |
| 1995 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Myxoma trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 3 |
| Observational | 4 |
How many Myxoma trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Myxoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Myxoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal Pain - Grade 3 (Unrelated) | 3 | 1 |
| Abdominal Distension - Grade 3 (Unrelated) | 1 | 1 |
| Abdominal Pain - Grade 3 (Unlikely Related) | 1 | 1 |
| Constipation - Grade 2 (Unrelated) | 1 | 1 |
| Edema Limbs - Grade 2 (Unlikely Related) | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Myxoma? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Carney complex predisposes to breast cancer: prospective study of 50 women. | European journal of endocrinology | 2024 | Yes |
| Predicting the risk of cardiac myxoma in Carney complex. | Genetics in medicine : official journal of the American College of Medical Genetics | 2021 | Yes |
| Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma. | Journal of cardiothoracic and vascular anesthesia | 2014 | Yes |
| The pilomyxoid astrocytoma and its relationship to pilocytic astrocytoma: report of a case and a critical review of the entity. | Journal of neuro-oncology | 2007 | Yes |
| Soft-tissue tumors evaluated by line-scan diffusion-weighted imaging: influence of myxoid matrix on the apparent diffusion coefficient. | Journal of magnetic resonance imaging : JMRI | 2007 | Yes |
Showing 5 of 15 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.